Program
Donepezil
Also written as “Donepezil Hydrochloride”, “E2020” and “Donepezil TDS”.
Its studies are mostly in Alzheimer Disease · Down Syndrome · Lewy Body Disease · Cognitive Dysfunction · Dementia, led by 14 companies.
Drug pageDonepezil: every studyMany companies study it; this page follows only the 79 they lead. All 184 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisaiits history only | 391 open or running | phase 4since Sep 12, 2005 | Nov 9, 2004 | May 6, 2030phase 1 · NCT07768592 |
| Pfizer | 70 open or running | phase 4since Sep 9, 2005 | Sep 8, 2005 | none ahead |
| Coriumits history only | 60 open or running | phase 1since Nov 13, 2016 | Nov 13, 2016 | none ahead |
| Merckits history only | 50 open or running | phase 2since Feb 14, 2014 | Oct 21, 2008 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 40 open or running | phase 1since Jan 3, 2012 | Jan 3, 2012 | none ahead |
| Teva Pharmaceutical Industriesits history only | 40 open or running | phase 1since Dec 14, 2010 | Dec 14, 2010 | none ahead |
| AstraZenecaits history only | 30 open or running | phase 1since Jul 9, 2008 | Jul 9, 2008 | none ahead |
| Icure Pharmaceuticalits history only | 30 open or running | phase 3since Jun 22, 2017 | May 15, 2013 | none ahead |
| GlaxoSmithKlineits history only | 20 open or running | phase 2since Jun 30, 2006 | Jun 30, 2006 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | phase 1since Jan 11, 2011 | Jan 11, 2011 | none ahead |
| AbbVieits history only | 10 open or running | phase 2since Aug 27, 2015 | Aug 27, 2015 | none ahead |
| Dongkook Pharmaceuticalits history only | 10 open or running | phase 1since Feb 18, 2016 | Feb 18, 2016 | none ahead |
| Teikoku Pharma USAits history only | 10 open or running | phase 2since Jun 5, 2009 | Jun 5, 2009 | none ahead |
| Theranexusits history only | 10 open or running | phase 1since Oct 2, 2018 | Oct 2, 2018 | none ahead |
Also a collaborator on its studies: PT Equilab International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pfizer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 8, 2005First study: phase 3 study in Dementia, VascularFirst studyNCT00174382 · 149 enrolled · Canada
- Sep 9, 2005Phase 4 study in Postoperative ComplicationsNCT00182845 · 30 enrolled · United States
- Apr 27, 2007No phase study in Alzheimer DiseaseNCT00467766 · 300 enrolled · United States, Australia, United Kingdom
- Jun 5, 2007No phase study in Alzheimer DiseaseNCT00483028 · 38 enrolled · United States
- Feb 27, 2008Phase 3 study in Alzheimer DiseaseNCT00630851 · 249 enrolled · Sweden
- Aug 14, 2009Phase 1 study in Alzheimer DiseaseNCT00959881 · 47 enrolled · United States
- Feb 26, 2010No phase study in Alzheimer DiseaseNCT01082965 · 18 enrolled · United States
TargetBeta
“Acetylcholinesterase inhibitor”ChEMBL 37, by rule
Other programs on ACHE
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| huperzine Arule | wanbangde-pharmaceutical-group-co-ltd | phase 4 | 7 |
| benzgalantamine gluconaterule | alpha-cognition-inc | phase 4 | 1 |
| Z 338rule | Zeria Pharmaceutical | phase 3 | 12 |
Studies
All 7 Pfizer leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01082965Alzheimer Disease · United States | – | Terminated | Jul 2012 | 18 |
| NCT00959881Alzheimer Disease · United States | 1 | Completed | Nov 2009 | 47 |
| NCT00630851Alzheimer Disease · Sweden | 3 | Completed | 249 | |
| NCT00483028Alzheimer Disease · United States | – | Completed | 38 | |
| NCT00467766Alzheimer Disease · United States, Australia, United Kingdom | – | Completed | 300 | |
| NCT00182845Postoperative Complications · United States | 4 | Completed | Apr 2007 | 30 |
| NCT00174382Dementia, Vascular · Canada | 3 | Terminated | Apr 2008 | 149 |
How it is read
Names in the registry
- “Donepezil”, 26 entries
- “Donepezil Hydrochloride”, 14 entries
- “E2020”, 7 entries
- “Donepezil TDS”, 5 entries
- “Donepezil hydrochloride”, 5 entries
Conditions, from the studies’ own filings
- Alzheimer Disease, 38 studies
- Down Syndrome, 5 studies
- Lewy Body Disease, 4 studies
- Cognitive Dysfunction, 3 studies
- Dementia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.